The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain...It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefits to patients.
-Russel Katz, MD, Director of the Division of Neurology Products in the FDA's center for Drug Evaluation and Research
Market Data 
Markets 
AI
